DYNLL1 and esophageal squamous cell carcinoma: These multimodal findings establish DYNLL1-AS1 as a theranostically actionable regulator of radiotherapy-induced immunosuppression through coordinated TAMs reprogramming and adaptive immune evasion, while providing a theranostic biomarker for optimizing radio-immunotherapy synergy in ESCC.